Editorial

Achievements and challenges in normal tissue response modelling for proton therapy

Normal Tissue Complication Probability (NTCP) models are used to describe the relationship between the dose distribution to critical organs at risk and the development of a given radiation-induced side effect [1–3]. For head and neck cancer (HNC), NTCP models are typically based on multivariate logistic regression, which in addition to dose/volume based predictors may include variables related to baseline data as well as patient- and disease related factors. The model based approach (MBA) for selecting patients to proton therapy makes use of NTCP models to identify patients where proton therapy can be beneficial in terms of reduced side effects. The criterion for qualifying for proton therapy (or for inclusion into a clinical trial) is based on a reduction in NTCP ($\Delta$NTCP) with protons compared to photons, and where the severity of the side effect of interest is reflected in a predefined threshold value. A detailed description of the methodology has previously been published [4,5], and the MBA has been accepted as a method to select patients to proton therapy by the Dutch health authorities. A wide range of NTCP models for common acute and late side effects after radiotherapy for HNC have been developed and are currently in use in the Netherlands [6,7]. The clinical experience with the MBA for selection of patients to proton therapy in HNC was recently reported by Tambas et al. [8]. By applying a $\Delta$NTCP threshold of 5 % for grade III and 10 % for grade II side effects, 35 % of the patients were selected for protons. Predominantly, patients qualifying for proton therapy had locally advanced pharyngeal cancers, and were selected on the basis of the estimated reduction in NTCP for xerostomia and dysphagia. The authors reported the MBA to be time-consuming, especially during the learning curve period, but still clinically feasible.

The use of MBA in clinical practice requires the availability of NTCP models with high predictive power. During NTCP model development challenges such as missing data, multicollinearity, selection of relevant predictors and identification of non-linear relationships between the outcome and continuous variables are addressed in order to create well-fitted models [9]. The apparent performance of an NTCP model will usually be overly optimistic. To avoid overfitting of the data internal model validation is recommended, preferably by applying bootstrapping procedures where all steps in model development are repeated on several randomly sampled data sets. Discrimination and calibration are then assessed in both the original and bootstrap samples after which the model is corrected for optimism [9,10]. Despite this, the model’s predictive power is typically reduced when used in new patients. However, validation of previously published NTCP models on own patient cohorts with model adjustments may improve prediction and is a prerequisite before clinical implementation of the model of interest.

Recently, a previously published NTCP model for dysphagia [11] was externally validated in a Danish patient cohort [12] and in the current volume of this journal, Kalendrais et al. [13] report the results from an external validation of an NTCP model for grade II dysphagia in 270 HNC patients. Both studies applied the closed testing procedure [14], which is an automated method that evaluate to what degree an NTCP model needs to be adjusted in order to improve performance when applied in the new patient cohort. The results from the external validation in the above mentioned studies differed, in the Danish patient cohort, updating the intercept resulted in a significant improvement in the model performance, whereas re-estimation of model coefficients significantly improved the performance in Kalendrais et al. [13].

The implementation of the MBA is challenging for several reasons. It requires prospective patient follow-up with continuous data collection for NTCP model development and validation, as well as patient registries for assessment of potential clinical benefits. Regular validation of the NTCP models is needed to ensure reliable models that are adjusted to changes in patient cohorts, treatment regimens and treatment techniques. Thus, the MBA is a resource-intensive methodology, and implementation in small centers with a limited number of patients may be challenging.

Furthermore, uncertainties in the NTCP models (i.e. predictor coefficients) as well as uncertainties in the actual delivered dose distributions could have a substantial impact on the accuracy of patient selection in the MBA. As shown by Bijman et al. [15], dose uncertainties could result in a selection accuracy as low as 60 %. In proton therapy, the clinically used constant relative biological effectiveness (RBE) factor of 1.1 is an additional pitfall [16]. It is becoming widely recognized that the RBE is not constant, but depends on parameters such as tissue $\alpha/\beta$, dose and fraction sizes, as well as spatially varying depending on the linear energy transfer (LET), which represents radiation quality [17]. Preclinical evidence of the variable RBE effect is solid, but the proof of clinical impact remains statistically weak [18].

The attraction of proton therapy is its potential reduction of morbidity in patients by better sparing of healthy tissue, however, at the same time there is concern of toxicity in critical organs at risk if the effective dose delivered is higher than expected at the distal edge of a beam. In addition, proton beams are less robust against anatomical changes occurring throughout the course of treatment. In particular, for HNC patients, tumor shrinkage or changes in the filling of air cavities/sinususes may result in deviations from the planned dose distribution. For HNC involving the skull base, these effects could lead to substantial increase in biological response in adjacent brain tissue. Kitpanit et al.
found an overall risk of brain necrosis after proton therapy to be 7 % (at 2-year follow-up in 234 patients), of where the majority (50%) presented in the temporal lobes [19]. The implementation of different dose constraints during proton planning was suggested to mitigate risk for these patients. Based on radiographic changes in 9/60 nasopharyngeal carcinoma patients treated with proton therapy, versus 20/506 patients treated with photon-based intensity modulated radiation therapy, Zhang et al. estimated the RBE for radiographic changes in the temporal lobe to be 1.18 [20]. Engeseth et al. found that 17% of 127 patients had radiation-induced brain image changes (asymptomatic) following proton therapy of skull base HNC [21], with a statistical significant association to volumes receiving high doses in combination with increased LET [22]. Contrary, Niemierko et al. found no correlation between brain necrosis and LET in 50 HNC patients treated with protons [23].

As a consequence of existing uncertainties, strategic choices of beam configuration to avoid positioning of beams in organs at risk is implemented in proton therapy. This practice comes with somewhat unknown clinical impact, and at the very least represents a limitation during treatment planning. In addition, dose reporting for patient records and studies may be inappropriate and is a limiting factor for accumulating clinical evidence. In fact, phenomenological modeling based on in-vitro experiments have demonstrated that most dose/volume based indices used to evaluate tolerance doses are underestimated for a wide range of diagnoses when using an RBE of 1.1 [24], including for HNC [25]. Furthermore, a standardized reporting of LET is lacking, and can diverge by an order of magnitude depending on how the LET is defined (i.e. track-averaged, dose-averaged, LET spectrum or not mentioned) [26]. Clinical studies may further be obscured by the noise level of retrospective study designs, origin of e.g. necrosis, voxel-based analysis and assumptions of independence, creating a need for large multi-center and multi-country studies to reach the required effect size. Wagenaar et al. recently discussed how the number of HNC patients required to conclude on a toxicity relation of mean dose times dose-averaged LET would be unfeasibly high [27]. Choice of study design, selection of patients at risk of high dose and LET may be key, and new concepts such as e.g. dose-LET volume histogram [28] can be useful predictors. In addition, Yang et al. recently estimated empirical RBEs for mandible osteoradionecrosis in HNC patients treated with pencil beam scanning protons versus photon-based volumetric modulated arc therapy, using a case-matched cohort design. Depending on dose cut-off, the estimated RBEs were 1.24–1.58 at moderate dose levels [29]. Evidently, there is a need for conventions and development of appropriate methods for clinical studies of proton RBE, and to harmonize LET collection across centers [30].

The direct application of photon-based NTCP models in proton treated patients can lead to imprecise morbidity predictions, due to substantially different model parameters across the modalities [31,32]. Toxicities and NTCP in proton therapy are also more affected by inter-patient variability in α/β values typical of brain tissues than have been shown to increase the RBE [33]. Toxocities and NTCP in proton therapy are also more affected by inter-patient variability in α/β compared to photon-based therapy, and thereby have increased sensitivity to inter-patient variability in α/β [34]. Not only the RBE but also NTCP depend on α/β, and the relative NTCP as function of α/β does not simply scale with the RBE. Dependency of RBE on α/β should therefore not be interpreted independently of NTCP.

In summary, the contribution of Kalendralis et al. [13] in the current volume is an important achievement within a research area that is essential for the further expansion of the scientifically founded indications of proton therapy.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] Arscott WT, Thompson RF, Yin L, Burgdorf B, Kirk M, Ben-Josef E. Stereotactic body proton therapy for liver tumors: Dosimetric advantages and their radiobiological and clinical implications. Phys Imaging Radiat Oncol 2018:8:17–22.
[2] Yoshimura T, Nishioka K, Hashimoto T, Seki K, Kogame S, Tanaka S, et al. A treatment planning study of urethra-sparing intensity-modulated proton therapy for localized prostate cancer. Radio Imaging Radiat Oncol 2021:20:25–9.
[3] Oonsiri S, Kitpanit S, Kannarunsmiti D, Chakrabatit L, Berltbutsayangkul C, Prayongrat A. Comparison of intensity modulated proton therapy beam configurations for treating thoracic esophageal cancer. Phys Imaging Radiat Oncol 2022: 22:20–6.
[4] Langendijk JA, Lambin P, De Ruyscher D, Widder J, Bos M, Verheij M. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol 2013:107:207–73.
[5] Wiener J, van der Schaar LA, Lam F, Marinjen CM, van Wezel E, van der Wall C, et al. A quest for evidence for proton therapy: model-based approach and precision medicine. Int J Radiat Oncol Biol Phys 2016:95:30–6.
[6] Langendijk JA, Hoebers FJP, de Jong MA, Doornaert P, Terhaarden CHJ, Steenhakkers RJHM, et al. National Protocol for model-based selection for proton therapy in head and neck cancer. Int J Part Ther 2021:8:354–65.
[7] Van den Bosch L, van der Schaaf A, van der Laan HP, Hoebers FJP, Wijers OB, van den Hoek JGM, et al. Comprehensive toxicity risk profiling in radiation therapy for head and neck cancer: A new concept for individually optimised treatment. Radiother Oncol 2021:157:147–54.
[8] Tamba M, van der Laan HP, Steenhakkers RJHM, Doyen J, Timmernann B, Orlandi E, et al. Current practice in proton therapy delivery in adult cancer patients across Europe. Radiother Oncol 2022:167:7–13.
[9] Van den Bosch L, Schuit E, van der Laan HP, Reitsma JB, Moons KGM, Steenhakkers RJHM, et al. Key challenges in normal tissue complication probability model development and validation: towards a comprehensive strategy. Radiother Oncol 2020:148:151–6.
[10] Steyerberg EW. Overfitting and optimism in prediction models. Clinical Prediction Models: A practical approach to development, validation, and updating. New York, NY: Springer New York 2009, p. 83-100.
[11] Christiansen ME, Schnibbe C, Breitl M, Mijui CT, Chouvalova O, Burlage FR, et al. Predictive modelling for swallowing dysfunction after primary (chemo)radiation: results of a prospective observational study. Radiother Oncol 2012:105:107–14.
[12] Hansen CR, Friborg J, Jemsen K, Samue E, Johnson L, Zulkukakie R, et al. NTCP model validation method for DAHANCA patient selection of protons versus photons in head and neck cancer radiotherapy. Acta Oncol 2019:58:1410–5.
[13] Kalendralis P, Sloop M, Moni George N, Jemsen K, Samue E, Johnson L, Zulkukakie R, et al. NTCP model validation method for DAHANCA patient selection of protons versus photons in head and neck cancer radiotherapy. Int J Radiat Oncol Biol Phys 2020:22:44–52.
[14] Vergouw Y, Nieboer D, Oostenbrink R, Debruyne TPA, Murray GD, Kattan MW, et al. A closed testing procedure to select an appropriate model for updating prediction models. Stat Med 2017:36:4529–39.
[15] Bijman RG, Breedveld S, Arts T, Astraenius E, de Jong MA, Granston PV, et al. Impact of model and dose uncertainty on model-based selection of orthopalladine cancer patients for proton therapy. Acta Oncol 2017:56:1444–50.
[16] Engeseth GM, Hysing LB, Yepes P, Pettersen HES, Mohan R, Fuller CD, et al. Impact of RBE variations on risk estimates of temporal lobe necrosis in patients treated with intensity-modulated proton therapy for head and neck cancer. Acta Oncol 2022:62:215–22.
[17] Pagannetti H, Blakely E, Canabal Fernandez A, Carlson DJ, Das IJ, Dong L, et al. Report of the AAPM TG-256 on the relative biological effectiveness of proton beams in radiation therapy. Med Phys 2019:46:e52–78.
[18] Underwood TSA, McNamara AI, Appel A, Haviland JS, Sørensen BS, Troost EGC. A systematic review of clinical studies on variable proton Relative Biological Effectiveness (RBE). Radiother Oncol 2022:175:79–92.
[19] Kitpanit S, Lee A, Pitter EL, Fan D, Chow JCH, Neal B, et al. Temporal lobe necrosis in head and neck cancer patients after proton therapy to the skull base. Int J Part Ther 2020:6:17–28.
[20] Zhang YY, Huo WL, Goldberg SJ, Slater JM, Adams JA, Deng XW, et al. Brain-specific relative biological effectiveness of protons based on long-term outcome of patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2021:110:984–92.
[21] Engeseth GM, Stieb S, Mohamed ASR, He R, Stolkovách GH, Bryd EJ, et al. Outcomes and patterns of radiation associated brain image changes after proton therapy for head and neck skull base cancers. Radiother Oncol 2020:151:119–25.
[22] Engeseth GM, He R, Mirkovic D, Yepes P, Mohamed ASR, Stieb S, et al. Mixed effect modeling of dose and linear energy transfer correlations with brain image changes after intensity modulated proton therapy for skull base head and neck cancer. Int J Radiat Oncol Biol Phys 2021:111:684–92.
[23] Niemierko A, Schuenneman J, Niyazi M, Giantsoudi D, Maqgian G, Shih HA, et al. Brain necrosis in adult patients after proton therapy: Is there evidence for dependency on linear energy transfer? Int J Radiat Oncol Biol Phys 2021:109:109–19.
[24] Rorvik E, Fjaera LF, Dahle TJ, Dale JE, Engeseth GM, Stolkovách GH, et al. Exploration and application of phenomenological RBE models for proton therapy. Phys Med Biol 2018:63:38501.
[25] Yepes P, Adair A, Frank SJ, Grossman DB, Liao Z, Liu A, et al. Fixed- versus variable-RBE computations for intensity modulated proton therapy. Adv Radiat Oncol 2019:4:156–67.
[26] Kalholm F, Grzanka L, Traneus E, Bassler N. A systematic review on the usage of averaged LET in radiation biology for particle therapy. Radiother Oncol 2021;161:211–21.

[27] Wagenaar D, Schuit E, van der Schaaf A, Langendijk JA, Both S. Can the mean linear energy transfer of organs be directly related to patient toxicities for current head and neck cancer intensity-modulated proton therapy practice? Radiother Oncol 2021;165:158–69.

[28] Yang Y, Vargas CE, Bhangoo RS, Schild SE, Daniels TB, et al. Exploratory investigation of dose-linear energy transfer (LET) volume histogram (DLVH) for adverse events study in intensity-modulated proton therapy (IMPT). Int J Radiat Oncol Biol Phys 2021;110:1189–99.

[29] Yang Y, Muller OM, Shirashi S, Harper M, Amundson AC, Wong WW, et al. Empirical relative biological effectiveness (RBE) for mandible osteoradionecrosis (ORN) in head and neck cancer patients treated with pencil-beam-scanning proton therapy (PBSPPT): A retrospective, case-matched cohort study. Front Oncol 2022;12:43175.

[30] Hahn C, Oden J, Daou A, Vestergaard A, Fuglsang Jensen M, Sokol O, et al. Towards harmonizing clinical linear energy transfer (LET) reporting in proton radiotherapy: a European multi-centric study. Acta Oncol 2022;61:206–14.

[31] Pedersen J, Flamponi S, Bryant C, Liang X, Mendenhall N, Li Z, et al. Cross-modality applicability of rectal normal tissue complication probability models from photon- to proton-based radiotherapy. Radiother Oncol 2020;142:253–60.

[32] Pedersen J, Liang X, Bryant C, Mendenhall N, Li Z, Muren L-P. Normal tissue complication probability models for prospectively scored late rectal and urinary morbidity after proton therapy of prostate cancer. Phys Imaging Radiat Oncol 2021;20:62–8.

[33] Paganetti H. Relating proton treatments to photon treatments via the relative biological effectiveness—should we revise current clinical practice? Int J Radiat Oncol Biol Phys 2015;91:892–4.

[34] Paganetti H. Relating the proton relative biological effectiveness to tumor control and normal tissue complication probabilities assuming interpatient variability in alpha/beta. Acta Oncol 2017;56:1379–86.

Grete May Engeseth
Dept of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway

Camilla Stokkevåg
Dept of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway

Ludvig P. Muren
Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark

* Corresponding author.
E-mail address: grete.may.engeseth@helse-bergen.no (G.M. Engeseth).